Valerie Leroy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Onxeo: Proceedings of the Combined Shareholders Meeting of June 15, 2022

Onxeo: Proceedings of the Combined Shareholders Meeting of June 15, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesFrance generalShefali agarwalArthur rouillOnxeo sa euronextValerie leroyEmmanuel huynhOlayan groupAmerican university of beirutCompany groupWall streetKhalil barrageManaging directorEuronext growth parisNasdaq first north copenhagen

Onxeo S A : Onxeo: Publication of the 2021 Annual Financial Report

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development

France generalArthur rouillOnxeo sa euronextValerie leroyEmmanuel huynhCompany groupRegulatory newsEuronext growth parisNasdaq first north copenhagenEuronext parisNasdaq first north

Onxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 Million

> Cash position of €17.9 million as of December 31, 2021 > Additional financing of €12 million subscribed by historical shareholders Invus and Financière de la Montagne in the form of the issuance

United statesFrance generalJulien miaraAcrotech biopharmaJudith grecietEmmanuel huynhArthur rouillOnxeo sa euronextRobertl colemanValerie leroyGustave roussyBryan giraudoInstitut curieGossamer bio incAudit committeeTrademark office

Onxeo to Present New Preclinical Data Highlighting AsiDNA s Ability to Fight Tumor Resistance and Protect From Anticancer Treatment Toxicity at AACR Annual Meeting 2022

AsiDNA proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA proven to protect healthy cells when combined with conventional antitumor treatments Regulatory

United statesFrance generalWael jdeyNicolas merigeauOnxeo sa euronextValerie leroyEmmanuel huynhMarie dutreix institut curieAmerican association for cancer research annual meetingGilles favre cancer research centerCompany groupEuronext growth parisFirst north copenhagenAmerican associationCancer research annual meetingGilles favre

Onxeo S A : Onxeo s New Preclinical Data Confirm the Relevance of Combining AsiDNA With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or

France generalWael jdeyNicolas merigeauOnxeo sa euronextValerie leroyEmmanuel huynhAnticancer therapies congressCompany groupEuronext growth parisFirst north copenhagenPreclinical leadEuronext parisNasdaq first north